Gutenberg Open Science: Eslicarbazepine acetate as adjunctive therapy for primary generalized tonic-clonic seizures in adults : a prospective observational study

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8397

Full metadata record

DC Field	Value	Language
dc.contributor.author	Winter, Yaroslav	-
dc.contributor.author	Sandner, Katharina	-
dc.contributor.author	Vieth, Thomas Ludger	-
dc.contributor.author	Melzer, Nico	-
dc.contributor.author	Klimpe, Sven	-
dc.contributor.author	Meuth, Sven G.	-
dc.contributor.author	Groppa, Sergiu	-
dc.date.accessioned	2023-01-17T11:28:06Z	-
dc.date.available	2023-01-17T11:28:06Z	-
dc.date.issued	2022	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/8413	-
dc.description.abstract	Background Eslicarbazepine acetate (ESL), a novel sodium channel blocker, is approved for mono and adjunctive treatment of partial epileptic seizures with or without secondary generalization. Its efficacy in primary generalized seizures has not yet been evaluated. Objective To evaluate the efficacy and safety of ESL in primary generalized tonic-clonic seizures (PGTCS) in an observational study. Methods The data were collected from a prospective population-based register. Effectiveness was measured as relative reduction in standardized seizure frequency (SSF), responder rate (≥ 50% reduction in SSF), and seizure freedom rate at 6 and 12 months after initiation of ESL. Safety and tolerability were evaluated using patients’ diaries. Results Fifty-six adult patients with PGTCS were treated with ESL as adjunctive therapy. Of these, 30.4% (n = 17) had myoclonic seizures in addition to PGTCS. The retention rate after 12 months was 80.4% (n = 45). After initiating ESL therapy, reduction in SSF for PGTCS on ESL was 56.0% after 6 months and 56.9% after 12 months (p < 0.01), whereas myoclonic seizures did not show any significant improvement in frequency. The responder rate for PGTCS was 64.3% after 6 months and 66.1% after 12 months, and seizure freedom was achieved in 32.1% and 35.7%, respectively. Forty-three patients (73.2%) reported no side effects. Among the reported side effects of ESL therapy, headache (7.1%), dizziness (8.9%), tiredness (7.1%), nausea (5.4%), and hyponatremia (5.4%) were the most prevalent. Conclusions Our data suggest that ESL may provide additional benefits in the treatment of patients with PGTCS and motivate randomized controlled trials in this indication.	en_GB
dc.description.sponsorship	Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577	de
dc.language.iso	eng	de
dc.rights	CC BY-NC	*
dc.rights.uri	https://creativecommons.org/licenses/by-nc/4.0/	*
dc.subject.ddc	610 Medizin	de_DE
dc.subject.ddc	610 Medical sciences	en_GB
dc.title	Eslicarbazepine acetate as adjunctive therapy for primary generalized tonic-clonic seizures in adults : a prospective observational study	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-8397	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 04 Medizin	de
jgu.organisation.number	2700	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	CNS Drugs	de
jgu.journal.volume	36	de
jgu.pages.start	1113	de
jgu.pages.end	1119	de
jgu.publisher.year	2022	-
jgu.publisher.name	Springer	de
jgu.publisher.issn	1179-1934	de
jgu.organisation.place	Mainz	-
jgu.subject.ddccode	610	de
jgu.publisher.doi	10.1007/s40263-022-00954-w	de
jgu.organisation.ror	https://ror.org/023b0x485	-
jgu.subject.dfg	Lebenswissenschaften	de
Appears in collections:	DFG-491381577-H

Files in This Item:

	File	Description	Size	Format
	eslicarbazepine_acetate_as_ad-20221124123642524.pdf		902.85 kB	Adobe PDF	View/Open

Show simple item record